Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Katy L. Simonsen"'
Autor:
Hussein A, Tawbi, Dirk, Schadendorf, Evan J, Lipson, Paolo A, Ascierto, Luis, Matamala, Erika, Castillo Gutiérrez, Piotr, Rutkowski, Helen J, Gogas, Christopher D, Lao, Juliana Janoski, De Menezes, Stéphane, Dalle, Ana, Arance, Jean-Jacques, Grob, Shivani, Srivastava, Mena, Abaskharoun, Melissa, Hamilton, Sarah, Keidel, Katy L, Simonsen, Anne Marie, Sobiesk, Bin, Li, F Stephen, Hodi, Georgina V, Long, Sajeve, Thomas
Publikováno v:
The New England journal of medicine. 386(1)
BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking a
Publikováno v:
Journal of biopharmaceutical statistics. 31(6)
This paper investigates the use of a general multi-arm multi-stage (MAMS) approach for time-to-event outcomes that would streamline simultaneous comparison of a large number of promising therapies in clinical trials, thus significantly reducing the t
Autor:
Jean-Jacques Grob, Evan J. Lipson, Bin Li, Erika Castillo Gutiérrez, Georgina V. Long, Shivani Srivastava, F. Stephen Hodi, Hussein Abdul-Hassan Tawbi, Helen Gogas, Piotr Rutkowski, Paolo A. Ascierto, Luis Matamala, Christopher D. Lao, Juliana Janoski de Menezes, Stéphane Dalle, Katy L. Simonsen, Mena Abaskharoun, Ana Arance, Dirk Schadendorf
9503 Background: Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. However, novel combinations are needed to optimize the benefit-risk profile. Lymphocyte-activation gene 3 (LAG-3) regulates an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::494b7104d9f2fb0f144b6df66dbffe5c
Autor:
Katy L. Simonsen, Adriana Comprelli, Paula M. Fracasso, Steven H. Bernstein, Cassidy James, Timothy P. Reilly, Megan Wind-Rotolo, Manish Gupta
Publikováno v:
European journal of cancer (Oxford, England : 1990). 103
Background The unprecedented success of immuno-oncology (I-O) agents targeting the cytotoxic T lymphocyte–associated antigen 4 and programmed death-1/programmed death-ligand 1 pathways has stimulated the rapid development of other I-O agents agains
Autor:
Christopher T. Harbison, Katy L. Simonsen, H.A. Tawbi, F.S. Hodi, Dirk Schadendorf, Victoria Atkinson, Georgina V. Long, Evan J. Lipson, Matthew Maurer
Publikováno v:
Annals of Oncology. 29:viii464-viii465
Autor:
Jack Hirsh, Stuart J. Connolly, Katy L. Simonsen, Sonia S. Anand, Guillaume Paré, Deepak L. Bhatt, Keith A.A. Fox, Salim Yusuf, Shamir R. Mehta, John W. Eikelboom
Publikováno v:
Paré, G, Mehta, S R, Yusuf, S, Anand, S S, Connolly, S J, Hirsh, J, Simonsen, K, Bhatt, D L, Fox, K A A & Eikelboom, J W 2010, ' Effects of CYP2C19 genotype on outcomes of clopidogrel treatment ', New England Journal of Medicine, vol. 363, no. 18, pp. 1704-14 . https://doi.org/10.1056/NEJMoa1008410
It has been suggested that clopidogrel may be less effective in reducing the rate of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 alleles that are associated with reduced conversion of clopidogrel to its active met
Autor:
Todd G. Kirchgessner, Carmen H. Tong, Olga Iakoubova, Marc S. Sabatine, James J. Devlin, Joseph J. Catanese, Christopher P. Cannon, Katy L. Simonsen, Charles M. Rowland, Eugene Braunwald, Koustubh Ranade
Publikováno v:
Journal of the American College of Cardiology. 51(4):449-455
Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes: Results from the PROVE IT-TIMI 22 StudyOlga A. Iakoubova, Marc S. Sabatine, Charles M. Rowland, Carmen H. Tong, Jo...
Publikováno v:
Journal of Construction Engineering and Management. 131:1310-1319
In spite of the efforts by government agencies, labor organizations, and researchers in the field of health and safety, injuries and fatalities continue to affect the construction industry. In 2002 the construction industry had the undesirable distin
Publikováno v:
Genetics. 170:2003-2011
It has been well established that gene expression data contain large amounts of random variation that affects both the analysis and the results of microarray experiments. Typically, microarray data are either tested for differential expression betwee
Publikováno v:
Oikos. 108:643-647
Popular procedures to control the chance of making type I errors when multiple statistical tests are performed come at a high cost: a reduction in power. As the number of tests increases, power for an individual test may become unacceptably low. This